Cells maintain homeostasis not only by controlling how fast proteins are built, but also by regulating how quickly they are destroyed. The primary cellular incinerator is the ubiquitin-proteasome system (UPS), where enzymes called E3 ligases append chains of a small protein tag, ubiquitin, onto target substrates. When these chains reach a specific length and topology—most notably via Lys48 (K48) linkages—they act as a degradation signal, routing the protein to the 26S proteasome for destruction.
However, pathological states like cancer, fibrosis, and metabolic disorders frequently hijack this system to keep key survival factors alive. By overexpressing specific deubiquitinating enzymes (DUBs) or utilizing molecular scaffolds, cells can systematically strip away these ubiquitin tags. This mechanism, known as deubiquitination-mediated protein stabilization, effectively resets the protein's degradation clock. It allows a cell to rapidly accumulate high steady-state concentrations of critical transcription factors, receptors, or metabolic enzymes without needing to alter their underlying gene transcription levels.
The Molecular Mechanics of Proteasomal Evasion
To understand why this stabilization strategy is so effective, one must look at the kinetic threshold of the proteasome. The proteasomal regulatory particle requires a stable, polyubiquitinated substrate to efficiently bind, unfold, and translocate a protein into its catalytic core. If a DUB removes these ubiquitin chains faster than an E3 ligase can attach them, the substrate's half-life extends dramatically.
[Target Protein] + [Ubiquitin Chain] --(E3 Ligase)--> [Tagged for Destruction]
|
[Target Protein] <---------------------(DUB)-------------------+
|
(26S Proteasome)
|
[Degradation]
This kinetic tug-of-war is highly sensitive to the specific topology of the ubiquitin chains. For example, Kai Zeng et al. demonstrated in USP22 upregulates ZEB1-mediated VEGFA transcription in hepatocellular carcinoma that the enzyme USP22 selectively removes both K48- and K63-linked ubiquitin chains from the transcription factor ZEB1. By shielding ZEB1 from proteasomal recognition, USP22 maintains high levels of the factor, which subsequently drives the transcription of the angiogenic signal VEGFA.
DUBs can also target non-canonical ubiquitin linkages to preserve oncogenic signaling. In USP1 inhibition suppresses the progression of osteosarcoma via destabilizing TAZ, Putao Yuan et al. showed that USP1 acts as a molecular bodyguard for the transcriptional co-activator TAZ by removing K11- and K29-linked polyubiquitin chains. This specific deubiquitination prevents TAZ from being recycled, allowing it to accumulate in the nucleus and activate gene programs associated with cell proliferation and metastasis. Similarly, Siyue Tao et al. established in The deubiquitinase UCHL1 negatively controls osteoclastogenesis by regulating TAZ/NFATC1 signalling that the deubiquitinase UCHL1 removes K48-linked polyubiquitin chains from TAZ to precisely control its post-translational abundance during bone remodeling.
The direct consequences of this failure in the normal degradation cycle are evident during cellular stress. Xiaohui Yu 0001 et al. observed in Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition that radiation exposure inhibits the normal ubiquitination of the replication factor CDC6. This stabilization allows CDC6 to persist in the nucleus, driving survival mechanisms that bypass treatment-induced cell death.
Upstream Regulatory Networks and Competitive Shielding
DUBs do not operate in isolation; their stability and recruitment are tightly orchestrated by upstream networks of non-coding RNAs and chaperone-like proteins that act as physical scaffolds.
One common method of regulation is the stabilization of the DUBs themselves via non-coding RNA pathways. As shown by Weitong Zhang et al. in Circ_DOCK1 regulates USP11 through miR-132-3p to control colorectal cancer progression, a circular RNA (circ_DOCK1) can sponge away microRNAs that would otherwise suppress the deubiquitinase USP11. The resulting abundance of USP11 allows it to continuously strip ubiquitin from downstream oncogenic factors, shielding them from the cell's recycling machinery.
Alternatively, non-coding RNAs can directly facilitate the recruitment of DUBs to their targets. Guohua Jin et al. reported in Exosome-mediated lncRNA SND1-IT1 from gastric cancer cells enhances malignant transformation of gastric mucosa cells via up-regulating SNAIL1 that exosome-delivered long non-coding RNAs promote the recruitment of deubiquitinating machinery to the invasive transcription factor SNAIL1, increasing its half-life and driving cellular transformation.
[lncRNA / Scaffold Protein]
|
+---> Binds [Target Protein] ---> Physically blocks E3 Ligase binding
|
+---> Recruits [DUB] ----------> Strips existing Ubiquitin tags
In some cases, stabilization is achieved through competitive binding that physically blocks E3 ligases from accessing the target protein. Youqin Xu et al. demonstrated this mechanism in The miR-1185-2-3p—GOLPH3L pathway promotes glucose metabolism in breast cancer by stabilizing p53-induced SERPINE1, where the protein GOLPH3L acts as a chaperone-like partner that physically interacts with SERPINE1. This interaction shields SERPINE1 from ubiquitination entirely, maintaining the high concentrations of metabolic enzymes required to sustain the rapid energy production of the Warburg effect. A similar structural scaffolding role was identified by Jing Zhao et al. in lncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer, where the long non-coding RNA GAS5 serves as a physical platform to stabilize the tumor suppressor YBX1, preventing its degradation and allowing it to activate downstream cell-cycle inhibitors.
Cross-Talk with Alternative Post-Translational Modifications
The cellular stability clock is not governed solely by the addition and removal of ubiquitin. Other post-translational modifications (PTMs)—such as SUMOylation, succinylation, and ISGylation—cross-talk with the UPS, either by competing for the same lysine residues or by altering the structural conformation of the protein to hide or reveal degradation motifs.
De-SUMOylation
SUMO (Small Ubiquitin-like Modifier) tags frequently serve as a prerequisite or alternative signal for protein turnover. In a single-author study, Yangjing Jiang demonstrated in Myeloid SENP3 deficiency protects mice from diet and age-induced obesity via regulation of YAP1 SUMOylation that the enzyme SENP3 removes SUMO tags from the pro-inflammatory signaling protein YAP1. This de-SUMOylation protects YAP1 from subsequent degradation, thereby sustaining the chronic inflammatory state of immune cells under metabolic stress.
Desuccinylation
The removal of succinyl groups from lysine residues can similarly dictate a protein's lifespan. Yiyun Yang et al. showed in Mechanism of desuccinylation of G6PD mediated by SIRT7 to promote vitiligo disease progression that the deacetylase SIRT7 desuccinylates the metabolic enzyme G6PD. This modification stabilizes G6PD, preventing its degradation and increasing its effective concentration within the cell. Conversely, Xiumei Huang et al. discovered in Antitumorigenic potential of Lactobacillus-derived extracellular vesicles: p53 succinylation and glycolytic reprogramming in intestinal epithelial cells via SIRT5 modulation that downregulating the desuccinylase SIRT5 leaves the tumor suppressor p53 in a stable, highly active succinylated state, preventing the metabolic reprogramming required for tumor growth.
ISGylation
The attachment of ISG15 (Interferon-Stimulated Gene 15) can directly interfere with the ubiquitination machinery by occupying identical target residues. Na Cui et al. reported in ISG15 accelerates acute kidney injury and the subsequent AKI-to-CKD transition by promoting TGFβR1 ISGylation that ISG15 modifies the TGF-β receptor 1 (TGFβR1). This ISGylation physically blocks the attachment of ubiquitin chains, preventing the receptor's proteasomal degradation and causing sustained, pathological pro-fibrotic signaling.
| Modification Type | Modulating Enzyme | Target Substrate | Downstream Functional Outcome |
|---|---|---|---|
| Deubiquitination | USP22 | ZEB1 | Promotes tumor angiogenesis |
| Deubiquitination | USP1 | TAZ | Drives osteosarcoma metastasis |
| De-SUMOylation | SENP3 | YAP1 | Sustains chronic inflammation |
| Desuccinylation | SIRT7 | G6PD | Increases enzyme concentration |
| ISGylation | ISG15 | TGFβR1 | Inhibits ubiquitination, drives fibrosis |
Therapeutic Exploitation of the Stabilization Clock
Mapping these stabilization pathways reveals significant therapeutic vulnerabilities. Many critical disease-driving proteins, such as transcription factors, have historically been considered "undruggable" because they lack well-defined small-molecule binding pockets. However, by targeting the specific DUBs or stabilizing scaffolds that keep these proteins alive, researchers can artificially accelerate their degradation.
For example, Tianyi Zhao et al. demonstrated in YY1-induced USP43 drives ferroptosis suppression by FASN stabilization and subsequent activation of SLC7A11 in ovarian cancer that ovarian cancer cells rely on the deubiquitinase USP43 to stabilize fatty acid synthase (FASN), which suppresses ferroptosis (iron-dependent cell death). Inhibiting USP43 strips away this protection, causing rapid FASN degradation and leaving the malignant cells vulnerable to lipid peroxidation.
Furthermore, disrupting these protective interactions can reverse drug resistance. As highlighted by Chenming Zeng et al. in Machado-Joseph Deubiquitinases: From Cellular Functions to Potential Therapy Targets, certain DUB subfamilies promote chemoresistance by continuously stabilizing anti-apoptotic factors. Combining standard chemotherapies with targeted DUB inhibitors prevents the removal of ubiquitin tags, allowing the cellular degradation machinery to clear out these survival factors and lowering the threshold required to trigger apoptosis in resistant tumors.